Therefore, the beneficial effects of HDAC inhibitors in the context of HD might be more complex than previously anticipated and encompass decreased class I deacetylase activity, increased degradation of HDAC2 and/or HDAC4 and a reduction in the transcription of Hdac11. This evidence concerns the gene HDAC9 and Huntington disease.